Genelux Corporation (GNLX) on Monday reported interim results from two ongoing trials evaluating Olvi-Vec in patients with progressive lung cancer: a Phase 1b/2 study in small cell lung cancer (SCLC) and a Phase 2 VIRO-25 study in non-small cell lung cancer (NSCLC).
In the Phase 1b/2 SCLC study, conducted in China by licensing partner Newsoara HYK Biopharmaceuticals, nine evaluable patients showed a 33% overall response rate (ORR) and a 67% disease control rate (DCR), with tumor shrinkage up to 85% in the highest-dose cohort. Olvi-Vec was generally well tolerated.
In the Phase 2 VIRO-25 NSCLC study in the U.S., five evaluable patients had a 60% DCR, with tumor reductions ranging from 8.9% to 22.7%. The therapy was generally well tolerated.
Additional interim data from both trials are expected throughout 2026. Topline results from a Phase 3 ovarian cancer trial are expected in the second half of 2026.
On Friday, Genelux shares had closed at $4.55, up 4.35%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.